Solid Biosciences Signed an Exclusive License Agreement with Armatus Bio for AAV-SLB101 in Facioscapulohumeral Muscular Dystrophy (FSHD)
Shots:
- Under the terms of the agreement, Armatus received a global non-exclusive license to use AAV-SLB101 for the treatment of FSHD along with AAV-SLB101 plasmid material, preclinical data characterizing AAV-SLB101 & manufacturing and regulatory know-how to enable development. Moreover, Armatus will be responsible for the development and commercialization of licensed products incorporating AAV-SLB101
- Solid Biosciences will receive an undisclosed amount in upfront payment, development & sales-based milestones, plus tiered royalties on net sales for any products incorporating AAV-SLB101
- AAV-SLB101 is a capsid that under preclinical evaluation depicted an increased transduction speed, enhanced skeletal & cardiac muscle tropism, decreased liver biodistribution & improved efficiency vs first-generation capsids
Ref: Solid Biosciences | Image: Solid Biosciences
Related News:- Solid Biosciences Entered into a Research Collaboration with Phlox Therapeutics to Develop New Therapies for Rare Cardiac Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
